Product Description
Mechanisms of Action: IL17A Inhibitor
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Livzon Group
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for LZM-012](https://pryzm-maps.s3.us-west-2.amazonaws.com/12current_maps.png)
Countries in Clinic: China
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Psoriasis
Phase 2: Spondylitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Psoriasis | P3 |
Recruiting |
Psoriasis |
2025-04-01 |
57% |
CTR20212135 | P2 |
Not yet recruiting |
Spondylitis |
None |
|
CTR20231931 | P3 |
Not yet recruiting |
Psoriasis |
None |
|
CTR20200990 | P1 |
Not yet recruiting |
Psoriasis |
None |